N-Acetyl Semax Amidate
Modified Semax with N-terminal acetylation and C-terminal amidation. Improves enzymatic stability and effective potency vs. parent Semax.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Marketed primarily via grey-market vendors as a longer-acting alternative to Semax. Russian-academy modifications target peptidase resistance. Independent Western RCTs absent.
All Western evidence is anecdotal. Counterfeit risk for nasal-spray form is elevated. Treat as Semax with extra speculation.
N-acetyl, C-amide modified Semax sequence for protease resistance.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
N-Acetyl Semax Amidate — primary mechanism: modified semax with n-terminal acetylation and c-terminal amidation. improves enzymatic stability and effective potency vs. parent semax.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 300-600 µg · daily, intranasal
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Not FDA-evaluated; research-grey